Company
Optimeos
Next generation nanoparticles advancing in vivo cell and gene therapies: beyond viral & LNP delivery
Also known as OPTIMEOS LIFE SCIENCES, INC.
- Status
- Operatingas of 2026-09-17
- Business model
- B2B
- Customers
- biopharmaceutical companies
- Legal name
- OPTIMEOS LIFE SCIENCES, INC.
Claim, correct or request removal
Record updated 28 September 2026
About
Optimeos is developing a solution suite to overcome crucial formulation challenges and address unmet medical needs.
Funding snapshot
- Total raised
- $4.4MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
- Latest round
- Grant2025-08-19
Funding rounds
- Round, 2026
- $1M2026-05-22, SEC form D sold, 1 investor
- Grant
- 2025-08-19
- Round, 2023
- $2.9M2023-06-26, SEC form D sold, 5 investors
- Round, 2021
- $175K2021-05-17, SEC form D sold, 4 investors
- Round, 2020
- $270K2020-08-06, SEC form D sold, 3 investors
Products
- Other
- CINCs
- Other
- LINCs
Loading relationship preview